Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Retrospective performance-indexed analysis of Thoroughbred racehorses undergoing surgical management of proximal sesamoid bone fractures.

Equine veterinary journal·2025
Same author

Letter re: A critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.

ESMO open·2025
Same author

Letter to the editor: what are the legal and ethical considerations of submitting radiology reports to ChatGPT?

Clinical radiology·2024
Same author

Leveraging metabolic modeling to identify functional metabolic alterations associated with COVID-19 disease severity.

Metabolomics : Official journal of the Metabolomic Society·2022
Same author

Development and validation of the Safe Sleep Calculator to assess risk of sudden unexpected death in infancy.

Scientific reports·2022
Same author

Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines.

Clinical radiology·2021
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 29, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 3, 2013

DCISに対する補助放射線療法です.

K Mokbel, C Choy, R Carpenter

    Lancet (London, England)
    |July 8, 2000
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
    05:31

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

    Published on: September 20, 2020

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    関連する実験動画

    Last Updated: Jun 29, 2026

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 3, 2013

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
    05:31

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

    Published on: September 20, 2020

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024